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Regulation of drug transporter expression by oncostatin M
in human hepatocytes
Abstract
The cytokine oncostatin M (OSM) is a member of the interleukin (IL)-6 family, known to
down-regulate expression of drug metabolizing cytochromes P-450 in human hepatocytes. The
present study was designed to determine whether OSM may also impair expression of
sinusoidal and canalicular drug transporters, which constitute important determinants of drug
hepatic clearance. Exposure of primary human hepatocytes to OSM down-regulated mRNA
levels of major sinusoidal solute carrier (SLC) influx transporters, including
sodium-taurocholate co-transporting polypeptide (NTCP), organic anion transporting
polypeptide (OATP) 1B1, OATP1B3, OATP2B1, organic cation transporter 1 and organic anion
transporter 2. OSM also repressed mRNA expressions of ATP binding cassette (ABC) efflux
transporters such as multidrug resistance protein (MRP) 2/ABCC2 and breast cancer resistance
protein/ABCG2, without however impairing those of multidrug resistance gene
1/P-glycoprotein/ABCB1, MRP3/ABCC3, MRP4/ABCC4 and bile salt export pump/ABCB11.
The cytokine concomitantly reduced NTCP, OATP1B1, OATP2B1 and ABCG2 protein
expression and NTCP and OATP transport activities. OSM effects towards transporters were
found to be dose-dependent and highly correlated with those of IL-6, but not with those of
other inflammatory cytokines such as tumor necrosis factor-α or interferon-γ. In addition,
OSM-mediated repression of some transporters such as NTCP, OATP1B1 and OATP2B1, was
counteracted by knocking-down expression of the type II OSM receptor subunits through
siRNA transfection. This OSM-mediated down-regulation of drug SLC transporters and
ABCG2 in human hepatocytes may contribute to alterations of pharmacokinetics in patients
suffering from diseases associated with increased production of OSM.
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ABSTRACT 
 
The cytokine oncostatin M (OSM) is a member of the interleukin (IL)-6 family, known to 
down-regulate expression of drug metabolizing cytochromes P-450 in human hepatocytes. 
The present study was designed to determine whether OSM may also impair expression of 
sinusoidal and canalicular drug transporters, which constitute important determinants of drug 
hepatic clearance. Exposure of primary human hepatocytes to OSM down-regulated mRNA 
levels of major sinusoidal solute carrier (SLC) influx transporters, including sodium-
taurocholate co-transporting polypeptide (NTCP), organic anion transporting polypeptide 
(OATP) 1B1, OATP1B3, OATP2B1, organic cation transporter 1 and organic anion 
transporter 2. OSM also repressed mRNA expressions of ATP binding cassette (ABC) efflux 
transporters such as multidrug resistance protein (MRP) 2/ABCC2 and breast cancer 
resistance protein/ABCG2, without however impairing those of multidrug resistance gene 
1/P-glycoprotein/ABCB1, MRP3/ABCC3, MRP4/ABCC4 and bile salt export 
pump/ABCB11.  The cytokine concomitantly reduced NTCP, OATP1B1, OATP2B1 and 
ABCG2 protein expression and NTCP and OATP transport activities. OSM effects towards 
transporters were found to be dose-dependent and highly correlated with those of IL-6, but not 
with those of other inflammatory cytokines such as tumor necrosis factor- or interferon-. In 
addition, OSM-mediated repression of some transporters such as NTCP, OATP1B1 and 
OATP2B1, was counteracted by knocking-down expression of the type II OSM receptor 
subunits through siRNA transfection. This OSM-mediated down-regulation of drug SLC 
transporters and ABCG2 in human hepatocytes may contribute to alterations of 
pharmacokinetics in patients suffering from diseases associated with increased production of 
OSM.  
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1. Introduction 
 
Oncostatin M (OSM) is a member of the interleukin (IL)-6 family, secreted mainly by 
monocytes, macrophages, T cells and polymorphonuclear neutrophils [1, 2]. Numerous 
biological activities have been ascribed to OSM, including for example differentiation of 
megakaryocytes, inhibition of tumor cell growth, induction of neurotrophic peptides and bone 
remodeling [2]. In the liver, OSM has been involved in various physiological processes 
including development and regeneration [3, 4]; this has been hypothesized to occur through 
activation of the type II OSM receptor expressed by hepatocytes and formed by the 
association of glycoprotein 130 (gp130) and OSM receptor  (OSMR) subunits [5, 6].  
 A well-recognized effect of OSM towards hepatocytes is the induction of acute-phase 
proteins such as C-reactive protein (CRP), thus supporting a role for OSM in liver 
inflammation [7, 8]. In addition, like other inflammatory cytokines such as IL-1, tumor 
necrosis factor (TNF)-, IL-6 and interferon (IFN)- [9, 10], OSM has been shown to alter 
expression of drug metabolizing enzymes; OSM-treated human hepatocytes thus exhibit 
reduced expression and activity of various cytochromes P-450 (CYPs) such as CYP1A2, 
CYP2B6 and CYP3A4 [11]. By contrast, whether OSM may concomitantly alter expression 
of other hepatic detoxifying proteins such as drug transporters, which constitute major actors 
of the drug hepatobiliary secretion pathway [12, 13] and are well-established targets for 
inflammatory cytokines [14-17], remains unknown. The present study was therefore designed 
to gain insight about this point, through investigating the expression of main solute carrier 
(SLC) transporters, involved in drug uptake at the sinusoidal pole of hepatocytes, and ATP-
binding cassette (ABC) transporters, usually acting as drug efflux pumps at the canalicular 
pole of hepatocytes, in OSM-treated primary human hepatocytes. Our data indicate that these 
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OSM-treated hepatocytes exhibit marked reduced expressions of SLC transporters and of 
some ABC transporters, with a global pattern of transporter changes close to that triggered by 
IL-6. These effects of OSM towards drug transporters, associated with known effects towards 
CYPs, may support the idea that up-regulation of OSM secretion in various physiological and 
pathological states may contribute to potential alteration of pharmacokinetics.     
 
2. Materials and methods 
 
2.1. Chemicals and reagents. 
 Recombinant human OSM was provided by R&D Systems (Minneapolis, MN). 
[
3
H(G)]taurocholic acid (sp. act. 1.19 Ci/mmol) and [6, 7-
3
H(N)]estrone-3-sulfate (sp. act. 
57.3 Ci/mmol) were purchased from Perkin Elmer Life Sciences (Boston, MA). Probenecid 
was from Sigma-Aldrich (Saint-Quentin Fallavier, France). Antibodies against the ABC 
transporters P-glycoprotein/multidrug resistance gene 1/ABCB1 and breast cancer resistance 
protein/ABCG2 were provided by Alexis Biochemicals (Lausen, Switzerland), whereas those 
against multidrug resistance-associated protein (MRP)2/ABCC2 and MRP3/ABCC3 were 
from Chemicon International (Temecula, CA), and those directed against the mitogen-
activated protein kinase (MAPK) phospho-extracellular signal regulated kinase (ERK) and 
total ERK from Cell Signaling Technology (Beverly, MA). All other compounds and reagents 
were
 
commercial products of the highest purity available. Vehicle for OSM was phosphate-
buffered saline; control cultures received the same dose of vehicle as treated counterparts. 
 
2.2. Cell isolation and culture.  
Human hepatocytes were obtained from adult donors undergoing hepatic resection for 
primary and secondary tumors, via the Biological
 
Resource Center (Rennes, France). Cells 
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5 
were prepared by perfusion of histologically-normal liver fragments using a collagenase 
solution [18]. They were primary cultured on plastic dishes in Williams’E medium, as already 
reported [19, 20]. All experimental procedures complied with French laws and regulations 
and were approved by the National Ethics Committee.  
 Human highly-differentiated hepatoma HepaRG cells were routinely cultured in 
Williams' E medium supplemented with 10% fetal calf serum, 100 IU/ml penicillin, 100 
μg/ml streptomycin, 5 μg/ml insulin, 2 mM glutamine, and 5 x 10–5 M hydrocortisone 
hemisuccinate; additional culture for two weeks in the same medium added with 2 % 
dimethyl sulfoxide was performed in order to get a full hepatocytic differentiation of the cells 
[21, 22]. 
 
2.3. SiRNA transfection 
SiRNA transfection was performed in HepaRG cells as previously described [23]. Briefly, 
HepaRG cells were trypsinized and replated in 24-multiwells with 100 nM chemically 
synthesized, double-stranded, siRNAs targeting mRNAs of gp130 or OSMR subunits, 
provided by Sigma-Aldrich, or control non-targeting siRNAs (si-NT), provided by 
Dharmacon (Lafayette, CO), in the presence of transfection medium, i.e. DharmaFECT-1 
transfection reagent (Dharmacon) diluted in DMEM optimum/Williams’E medium 
supplemented with 1% dimethyl sulfoxide. After 18 h, transfection medium was withdrawn 
and cells were next maintained for 72 h in Williams’E medium described above, before being 
treated with OSM.  
 
2.4. RNA isolation and analysis.  
Total RNA was isolated from cells using the TRIzol
R
 reagent (Invitrogen, Cergy-Pontoise, 
France). RNA was then subjected to reverse transcription-real time quantitative polymerase 
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6 
chain reaction (RT-qPCR) using the fluorescent dye SYBR Green methodology and an ABI 
Prism 7300 detector (Applied Biosystem, Foster City, CA), as already reported [24]. Gene 
primers for drug transporters and CRP were exactly as previously described [19]. Other 
primers were MRP4/ABCC4 sense, GCTCAGGTTGCCTATGTGCT, ABCC4 antisense, 
CGGTTACATTTCCTCCTCCA, OSMR sense, ATGCCATCATGACCTGGAA, OSMR 
antisense, CTCGCGCCATGTACTCTGT, gp130 sense, ATGAAGGTGGGAAGGATGG, 
gp130 antisense, TGCCTTGGAGGAGTGAG. Relative quantification of the steady-state 
target mRNA levels was calculated after normalization of the total amount of cDNA tested to 
a 18S endogenous reference.  
 
2.5. Western-blot analysis. 
Total cellular or crude membrane extracts were prepared from primary human hepatocytes as 
previously described [15]. Proteins were then separated on polyacrylamide gels and 
electrophoretically transferred to nitrocellulose membranes. After blocking in Tris-buffered 
saline containing 4 % bovine serum albumin, membranes were incubated overnight at 4°C 
with primary antibodies directed against sodium-taurocholate cotransporting polypeptide 
(NTCP)/SLC10A1, organic anion transporting polypeptide (OATP)2B1/SLCO2B1, 
OATP1B1/SLCO1B1 [25], P-glycoprotein/ABCB1, ABCC2, ABCC3, ABCG2, phospho-
ERK or total ERK.  Peroxidase-conjugated monoclonal antibodies were thereafter used as 
secondary antibodies. After washing, immuno-labelled proteins were visualized by 
chemiluminescence. Gel loading and transfer was checked up by staining membranes with 
Ponceau red. The intensities of stained bands were measured by densitometry using ImageJ 
1.40g software (National Institute of Health, Besthesda, MA).  
 
2.6. Transport assays.  
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7 
Transport activities due to NTCP or OATPs were analyzed through measuring sodium-
dependent-intracellular accumulation of the NTCP substrate taurocholate and probenecid-
sensitive uptake of the OATP substrate estrone-3-sulfate, as previously described [18]. 
Briefly, cells were incubated at 37°C for 10 min with 0.17 µM [
3
H]taurocholate in the 
presence or absence of sodium or with 1.7 nM [
3
H]estrone-3-sulfate in the presence or 
absence of the OATP inhibitor probenecid used at 2 mM. After washing in phosphate-
buffered saline, cells were lyzed and accumulation of radiolabeled substrates was determined 
through scintillation counting. Taurocholate accumulation values in the presence of sodium 
minus accumulation values in the absence of sodium and estrone-3 sulfate uptake values in 
the absence of probenecid minus uptake values in the presence of probenecid, are thought to 
represent NTCP- and OATP-related transport activities [18]. 
 
2.7. Statistical analysis.  
Quantitative data were usually expressed as means + SD. They were statistically analyzed 
using the Student’s t test, Kruskal-Wallis one-way analysis of variance followed by the 
Student-Newman-Keuls test, or the nonparametric Spearman's rank correlation method. The 
criterion of significance was p<0.05. Data from dose-response studies were fitted using the 
SigmaPlot software (Systat software, San Jose, CA).  
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3. Results 
 
3.1. Effects of OSM treatment on CRP expression. 
Primary human hepatocytes from 6 liver donors were exposed to 10 ng/ml OSM for 8 h, 24 h 
or 48 h. This concentration of OSM was retained since it has been previously used for treating 
cultured hepatic cells in various studies [7, 26, 27]; it did not exert toxicity as demonstrated 
by phase-contrast microscopic examination of the cultures (data not shown). As shown in 
Table 1, OSM markedly increased mRNA expression of CRP, whatever the exposure time, 
even if the level of induction varied according to hepatocyte populations; such a variety in the 
level of induction has already been reported for regulation of referent inflammatory markers, 
including CRP, by cytokines in human hepatocytes [16]. Since CRP is a well-established 
target of OSM [7], these data indicated that primary human hepatocytes were fully responsive 
to OSM in our hands and were thus suitable for investigating OSM effects towards drug 
transporter expression. 
 
3.2. Effects of OSM treatment on drug transporter mRNA expression. 
We first analyzed the effects of OSM treatment on SLC transporter mRNA expression by RT-
qPCR. As shown in Fig. 1A, human hepatocytes obtained from 6 individuals exhibited lower 
mRNA expression of OATP1B1, OATP1B3/SLCO1B3 and organic anion transporter 2 
(OAT2)/ SLC22A7, when exposed to OSM, comparatively to untreated counterparts, 
whatever the time of treatment (8 h, 24 h or 48 h). With respect to OATP1B3 and OAT2, the 
time of exposure did not affect the level of expression repression in a major way, i.e. reduced 
levels of transporter expression found in hepatocytes exposed to OSM for 8 h, 24 h or 48 h 
were not statistically different; by contrast, OATP1B1 expression was found to statistically 
decrease with the time of exposure (Fig. 1A). OSM was also found to repress organic cation 
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9 
transporter (OCT)1/SLC22A1, OATP2B1 and NTCP mRNA levels, but only in response to a 
24-h or 48-h exposure (Fig. 1A). 
We next studied the effects of OSM treatment on ABC transporter mRNA expression. 
As shown in Fig. 1B, expression of ABCB1, bile salt export pump/ABCB11, ABCC3 and 
ABCC4 remained statistically unchanged in hepatocytes exposed to OSM for 8 h, 24 h or 48 
h, when compared to untreated counterparts. By contrast, OSM down-regulated ABCC2 and 
ABCG2 expression, whatever the time of exposure; ABCC2 mRNA levels, unlike ABCG2 
mRNA levels, were however lower in hepatocytes exposed to 24-h or 48-h to OSM when 
compared to those found in counterparts exposed for only 8-h, suggesting a time-dependent 
effect of the cytokine towards mRNA levels of this transporter.  
When considering the repression factor after a 24-h exposure to OSM, i.e. the ratio of 
mRNA levels in untreated hepatocytes versus those found in treated counterparts, NTCP was 
the most repressed among the transporters affected by OSM, followed by OATP1B1, 
ABCG2, OATP2B1, OATP1B3, OCT1, ABCC2 and OAT2 (Table 2).  Interestingly, these 
transporters, excepted OAT2 which has not been analysed, were also found to be repressed by 
OSM in human highly differentiated hepatoma HepaRG cells (Table 2), known to represent a 
useful alternative to primary human hepatocytes for investigating hepatic detoxifying 
proteins, including transporters [22, 28]. A 8-h exposure to 10 ng/ml OSM moreover 
markedly induced CRP mRNA expression by a 517.4 + 264.0-fold factor in HepaRG cells, 
confirmating that these hepatoma cells were fully responsive to OSM.  
The dose-response relationship for OSM effects towards some transporters was next 
characterized in primary human hepatocytes. As shown in Fig. 2, repressing effects of OSM 
towards NTCP, OATP1B1, OATP1B3, OCT1, ABCC2 and ABCG2 were dose-dependent, 
with EC50 ranging around 0.1 to 1 ng/ml. Treatment by 20 ng/ml OSM led to down-
regulations of transporter expression similar to those observed with 10 ng/ml OSM. The use 
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10 
of OSM at 1 ng/ml also repressed transporters, but in a more moderate manner. The dose of 
0.1 ng/ml was still partially active, except for ABCG2, whereas the lower concentration of 
0.01 ng/ml has no obvious, or only very limited, effects on transporter mRNA expression 
(Fig. 2).   
 
3.3. Effects of OSM treatment on drug transporter protein expression. 
To determine whether some of the changes in transporter mRNA levels induced by OSM also 
occur at the protein level, we next performed Western-blot analysis of crude membranes from 
OSM-treated primary human hepatocytes and untreated counterparts. As indicated in Fig. 3, 
exposure to OSM for 48 h reduced expression of NTCP, OATP1B1, OATP2B1 and ABCG2. 
By contrast, it failed to obviously alter P-glycoprotein/ABCB1, ABCC2 and ABCC3 
expression (Fig. 3).  
 
3.4. Effects of OSM treatment on transporter activities. 
Owing to the limited availability of human hepatocytes, we focussed on the effects of 
cytokine treatments on activities of NTCP and OATPs, whose mRNA expressions were 
among the most repressed by OSM (Table 2).  As shown in Fig. 4, exposure to OSM for 48 h 
resulted in decreased NTCP and OATP transport activity in human primary hepatocytes, 
when compared to untreated counterparts.  
 
3.5 Correlation analysis of cytokine repressing effects on drug transporter mRNA expression 
in human hepatocytes. 
Besides OSM, various cytokines such as IL-1, TNF-, IL-6 and IFN-, have been previously 
shown to down-regulate mRNA expression of various hepatic transporters [15, 16, 29]. In 
order to search for a putative correlation between these repressive effects of cytokines, drug 
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11 
transporters were ranked according to the down-regulation of their mRNA expression in 
response to a 24-h treatment by cytokines. Data used for OSM effects were from Fig. 1, 
whereas those related to IL-1, TNF-, IL-6 and IFN-effects have been previously obtained 
using primary human hepatocytes cultured in the same conditions than those used in the 
present study [15, 19, 29]. For each treatment, transporters were ranked from the most 
repressed transporter to the less repressed according to mRNA expression levels. Correlations 
were analyzed using the Spearman’s rank correlation method. Results indicated that the 
effects of OSM towards drug transporters were highly correlated with those of IL-6 and, in a 
more moderate manner, with those of IL-1 (Fig. 5). By contrast, they were not correlated 
with those of TNF- and IFN-Fig
 
3.6 Involvement of type II OSM receptor in OSM effects towards drug transporters. 
To investigate the implication of the type II OSM receptor in the repressing effects of OSM 
towards drug transporters, we performed knock-down of its subunits OSMR and gp130 in 
HepaRG cells using siRNA transfection. As shown in Fig. 6A, HepaRG cells transfected with 
siRNAs targeting OSMR (si-OSMR) or gp130 (si-gp130) exhibited reduced expressions of 
OSMR and gp130 mRNAs, which represent less than 25% of mRNA levels found in control 
counterparts transfected with non-targeting siRNAs (si-NT). In order to determine whether 
these type II OSM receptor subunit down-regulations have functional consequences, we 
analyzed their implication towards OSM-mediated CRP mRNA induction. As indicated in 
Fig. 6B, si-OSMR- and si-gp130-transfected cells exposed to OSM exhibited reduced up-
regulation of CRP when compared to that occurring in control si-NT-transfected counterparts. 
Moreover, they also displayed reduced levels of phospho-ERK, whereas total ERK expression 
remained unchanged (Fig. 6C), knowing that the ERK pathway constitutes one of the major 
signaling events activated by OSM, i.e. ERK is activated through phosphorylation in response 
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to OSM [30]. Taken together, these data strongly suggest that siRNA-mediated repression of 
type II OSM receptor subunits was functionally relevant in HepaRG cells, i.e. it resulted in 
decreased activity of OSM. 
 We next analyzed the consequences of siRNA-mediated OSMR and gp130 subunit 
knockdown on OSM-mediated down-regulation of NTCP, OATP1B1 and OATP2B1, which 
are the three most repressed drug transporters in OSM-exposed HepaRG cells (Table 2).  
OSM-mediated repression of OATP1B1 and OATP2B1 was found to be counteracted in a 
major way by siRNA-mediated silencing of either OSMR (Fig. 7A) or gp130 (Fig. 7B) 
subunits of type II OSM receptor. OSM-related repression of NTCP was also significantly 
attenuated (Fig. 7A and 7B). 
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4. Discussion 
 
The data reported in the present study demonstrate that treatment by OSM can repress 
expression of major drug transporters in human hepatocytes. SLC transporters are notably 
affected in a major way, because OSM down-regulates mRNA levels of NTCP, involved in 
sinusoidal uptake of bile acids, of OATP1B1, OATP1B3, OATP2B1 and OAT2, involved in 
sinusoidal uptake of organic anions, and of OCT1, mediating sinusoidal uptake of organic 
cations, in a dose-dependent manner. Moreover, some of these transporters such as NTCP, 
OATP1B1 and OATP2B1 are also repressed at protein levels, and NTCP and OATP transport 
activities are concomitantly reduced by OSM.  
 OSM also targets ABC efflux transporters, but in a more limited manner. Indeed, if 
ABCG2 expression was repressed at both mRNA and protein level by OSM treatment in 
primary human hepatocytes, other major ABC transporters such as P-glycoprotein/ABCB1, 
ABCB11, ABCC3 and ABCC4 were not affected. With respect to the organic anion efflux 
transporter ABCC2,  its mRNA expression was down-regulated by OSM, whereas its protein 
expression remained unaltered; the reason for such a discrepancy remains unclear, but it could 
be linked to the relative low level of repression of ABCC2 mRNA expression by OSM in 
primary human hepatocytes (by only a 1.8-fold-factor after a 24-h exposure to OSM; Table 2) 
or could reflect divergent transcriptional and post-transcriptional effects of OSM towards 
ABCC2 expression. Such differential effects of cytokines towards mRNA and protein 
expressions of drug transporters have already been reported for the effects of IL-6 and TNF- 
towards some hepatic transporters. Indeed, IL-6 decreased ABCB1 mRNA levels in primary 
human hepatocytes, without however affecting P-glycoprotein content, whereas TNF- 
increased protein expression of ABCG2 and ABCC3, without concomitant changes in mRNA 
levels of these transporters [19].  
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 The mechanism by which OSM altered expression of transporters remains to be 
characterized. Type II OSM receptor, which has already been demonstrated to be implicated 
in hepatic effects of OSM [6], is most likely involved. Indeed, knock-down of gp130 and 
OSMR subunits of this receptor counteracted down-regulation of NTCP, OATP2B1 and 
OATP1B1 mRNA expression by OSM in HepaRG cells. It can therefore be hypothesized that 
signaling pathways that are activated by this receptor, especially by its signal-transducing 
component gp130 subunit, may play a major role in OSM-related changes in transporter 
expression. The fact that these transporter expression alterations due to OSM treatment were 
highly correlated with those triggered by exposure to IL-6 fully supports this hypothesis, 
because IL-6 receptor also uses gp130 subunit for transduction pathway [31]. Through gp130 
subunit, OSM and also IL-6, are known to activate several distinct signaling ways, including 
Janus kinase/signal transducer and activator of transcription cascade, MAPK pathway and 
phosphatidylinositol 3-kinase pathway [32]; in agreement with these data, the MAPK ERK 
was found to be activated by OSM in HepaRG cells (Fig. 6C).  Analysis of the role that may 
play these different signaling pathways in OSM-related transporter repression would likely 
deserve further studies. In this context, it is however noteworthy that the effects of OSM 
towards transporter were not correlated with those of TNF- or IFN-, suggesting that these 
cytokines mobilize independent signaling pathways for acting on transporters. With respect to 
the effects of IL-1 on transporters, a correlation with those of OSM was observed; this likely 
indicate some partial interrelationships or crosstalks between IL-1-signaling pathways and 
those linked to OSM with respect to hepatic transporter regulation. The fact that at least 
MAPKs and STAT3 can be activated by both OSM and IL-1 may support this hypothesis 
[15, 31, 33]. 
 The putative physiological and pathological relevance of OSM effects towards human 
hepatic transporter expression remains to be precisely described. OSM exposure is however 
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likely to result in reduced sinusoidal uptake of drugs, owing to its global repressing effect 
toward influx SLC transporters. In addition, OSM-mediated down-regulation of ABCG2 
expression may contribute to decreased biliary secretion of drugs such as the antibiotic 
nitrofurantoin handled by this canalicular ABC pump [34]. Associated with the known 
repression of drug metabolizing CYP activity triggerred by OSM, these putative alterations of 
hepatic drug transport may contribute to alteration of pharmacokinetics. Such impairment of 
drug disposition may have notably to be considered in subjects exhibiting elevated circulating 
levels of OSM, such as preeclamptic pregnant women [35] or patients suffering from 
rheumatoid arthritis [36], systemic lupus erythematosus [37], periodontal diseases [38] or 
malignant hemopathies [39].  In this context, it is noteworthy that patients with these diseases 
may display serum OSM levels up to 1 ng/ml [35], which are therefore in the range of OSM 
concentrations exhibiting repressing activity on hepatic transporters in vitro (Fig. 2); this 
supports the idea that OSM serum levels up-regulated in some diseases may be sufficient to 
affect in vivo expression of drug transporters. Moreover, elevated hepatic expression of OSM 
has been reported in liver-injury conditions and cirrhosis [5, 40] and this in situ hepatic 
production of OSM, in association with the up-regulation of other hepatic inflammatory 
cytokines such as IL-1, TNF- and IL-6, may therefore directly contribute to the decreased 
hepatobiliary secretion of drugs observed in these pathological situations [41]. In addition, the 
repressing effects of OSM towards NTCP expression and activity may lead to alteration of 
enterohepatic cycle of bile acids through impairment of their NTCP-mediated reuptake from 
blood at the sinusoidal pole of hepatocytes and, by this way, may contribute to cholestasis. 
Impairment of the biliary elimination of other endogeneous substrates for hepatic transporters, 
such as bilirubin handled by OATPs [42], may have also to be considered. Finally, it is 
noteworthy that OSM has been shown to impact brain endothelial cells and kidney tubular 
cells, which are well known to play a major role in drug disposition and elimination [30, 43, 
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44]; whether OSM may alter expression of drug transporters in these cells would likely 
deserve further studies.  
 In conclusion, the current data demonstrate that OSM down-regulates expression of 
drug transporters in human hepatocytes, especially that of sinusoidal uptake SLC transporters. 
Such changes may likely contribute to alterations of pharmacokinetics in patients suffering 
from diseases associated with increased production of OSM.  
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Legends to figures 
 
Fig. 1. Effects of OSM on drug transporter mRNA expression in human hepatocytes. 
Primary human hepatocytes were either untreated or exposed to 10 ng/ml OSM for 8 h, 24 h 
or 48 h. SLC (A) and ABC (B) transporter mRNA expression was then determined by RT-
qPCR, as described under Materials and Methods. Data are expressed for each transporter as 
percentage of expression found in control untreated hepatocytes, arbitrarily set at the value of 
100 %. They are the means + SD of values from six independent hepatocyte populations. *, 
p<0.05 when compared to untreated cells; #, p<0.05 when compared to cells exposed to OSM 
for 8 h; ¤, p<0.05 when compared to cells exposed to OSM for 24 h (Student-Newman-Keuls 
test). 
 
Fig. 2. Dose-response of OSM effects towards drug transporter expression. 
Primary human hepatocytes were either untreated or exposed to 0.01, 0.1, 1, 10 or 20 ng/ml 
OSM for 48 h. Transporter mRNA expression was then determined by RT-qPCR, as 
described under Materials and Methods. Data are expressed for each transporter as percentage 
of expression found in control untreated hepatocytes, arbitrarily set at the value of 100 %, and 
are the means + SD of values from four independent hepatocyte populations. They were fitted 
with OSM concentrations, allowing to determine OSM EC50 for each transporter regulation.   
 
Fig. 3. Effects of OSM on drug transporter protein expression in human hepatocytes. 
Primary human hepatocytes were either untreated or exposed to 10 ng/ml OSM for 48 h. 
Transporter protein content was then determined by Western-blot analysis. For each 
transporter, data were quantified by densitometric analysis and expressed relatively to 
transporter expression found in control untreated cells, arbitrarily set at the value of 100 %; 
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they are the means + SD of values from three (NTCP) or six (other transporters) independent 
hepatocyte populations (upper panel). A representative blot is also shown for each transporter 
(lower panel). *, p<0.05 when compared to untreated cells (Student’s t test).  
 
Fig. 4. Effects of OSM on drug transporter activities in human hepatocytes. 
Primary human hepatocytes were either untreated or exposed to 10 ng/ml OSM for 48 h. 
NTCP and OATP activities were then determined using radiolabeled substrates as described 
under Materials and Methods. Data are expressed relatively to transporter activity found in 
control untreated cells, arbitrarily set at the value of 100 %; they are the means + SD of values 
from five (NTCP activity) or six (OATP activity) independent hepatocyte populations. *, 
p<0.05 when compared to untreated cells (Student’s t test). 
 
Fig. 5. Rank correlation analysis of repressing effects of OSM, IL-6, TNF-, IL-1 and IFN- 
towards drug transporter mRNA expression in human hepatocytes. 
Drug transporters were ranked according to the down-regulation of their mRNA expression in 
response to a 24-h treatment by OSM, IL-6, TNF-, IL-1 and IFN-, from data from Fig. 1 
for OSM effects and from previous published data for the effects of the other cytokines       
[15, 19, 29]. For this purpose, transporters were ranked for each treatment from the most 
repressed transporter to the less repressed, through considering the repression factor for each 
transporter, i.e. the ratio of mRNA levels in untreated hepatocytes versus those found in 
treated counterparts. Correlations were analyzed using the Spearman’s rank correlation 
method. Spearman’s rank coefficients () and p values are provided on the top of each 
correlation graph. 
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Fig. 6. Functional repression of OSMR and gp130 subunits of the type II OSM receptor by 
siRNA mediated transfection.  
HepaRG cells were transfected with non-targeting siRNAs (si-NT) or with siRNAs targeting 
OSMR (si-OSMR) or gp130 (si-gp130) as described under Materials and Methods. (A) 
Expression of OSMR and gp-130 mRNAs was then determined by RT-qPCR. Data are 
expressed as percentage of expression found in control si-NT-transfected cells, arbitrarily set 
at the value of 100 %, and are the means + SD of values from four independent experiments. 
*, p<0.05 when compared to si-NT-transfected cells (Student’s t test). (B) Cells were exposed 
to 10 ng/ml OSM for 24 h. CRP mRNA expression was then determined by RT-qPCR; data 
are expressed as percentage of expression found in control OSM-untreated si-NT-transfected 
cells, arbitrarily set at the value of 100 %, and are the means + SD of values from four 
independent experiments. *, p<0.05 when compared to OSM-treated si-NT-transfected cells 
(Student-Newman-Keuls test). (C) Cells were exposed to 10 ng/ml OSM for 30 min. 
Phospho-ERK and total ERK contents were next analyzed by Western-blot. Data shown are 
representative of two independent experiments.  
 
Fig. 7. Effects of OSMR and gp130 subunit knock-down on OSM-mediated repression of 
drug transporters. 
HepaRG cells, transfected with non-targeting siRNAs (si-NT) or with siRNAs targeting 
OSMR (si-OSMR) or gp130 (si-gp130) subunits of the type II OSM receptor, were 
exposed to 10 ng/ml OSM for 24 h. Expression of the transporters NTCP, OATP1B1 and 
OATP2B1 was then determined by RT-qPCR in si-OSMR- (A) and si-gp130- (B) 
transfected cells, as described under Materials and Methods; data are expressed as percentage 
of expression found in control OSM-untreated si-NT-transfected cells, arbitrarily set at the 
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value of 100 %, and are the means + SD of values from five independent experiments. *, 
p<0.05 when compared to OSM-treated si-NT transfected cells (Student’s t test). 
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Table 1 
Effects of OSM treatment on CRP mRNA expression in primary human hepatocytes 
 
 Exposure time to              CRP mRNA expression       CRP mRNA fold-induction  
          OSM (% of 18 S) 
 
 
0 h 0.0002 + 0.0003    -  
 
8 h 0.0141 + 0.0102*      8453 + 9934*   
  
24 h 0.0567 + 0.0373*   32011 + 39266* 
 
48 h 0.0260 + 0.0171
*
        24695 + 43352* 
 
 
CRP mRNA fold-induction are defined as the ratio of CRP mRNA levels in OSM-treated primary 
hepatocytes versus those found in untreated counterparts. 
Data are mean + SD of values from six independent hepatocyte populations. 
*,
 
p<0.05 when compared to untreated hepatocytes (Student-Newman-Keuls test). 
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Table 2 
Repression of drug transporter expression in primary human hepatocytes and hepatoma HepaRG cells 
exposed to OSM 
 
 
       Fold repression (mRNA levels) 
           ________________________________________________________ 
  Transporter               Human hepatocytes                  HepaRG cells 
          
 
NTCP       9.8 + 6.2    17.0 + 2.9 
OATP1B1    3.6 + 1.2    4.6 + 0.6 
ABCG2    3.2 + 1.6    3.1 + 0.3  
OATP2B1    2.6 + 1.1    3.3 + 0.6 
OATP1B3    2.5 + 1.1    2.3 + 0.3 
OCT1     2.4 + 1.0    2.8 + 1.0 
ABCC2    1.8 + 0.5    2.8 + 0.4 
OAT2             1.8 + 0.7    Not Done 
 
Fold
  
repression are defined as the ratio of drug transporter mRNA levels in control untreated cells 
versus those found in counterparts exposed to 10 ng/ml OSM for 24 h.  
Data are the mean + SD of values from six independent populations (Human hepatocytes) or from 
three independent experiments (HepaRG cells).  
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